ArticleCancer science2018

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.

Ken Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.